
Product Data Sheet

Product Name: Natalizumab

Cat. No.: GC61109

Chemical Properties

Cas. No. 189261-10-7

SMILES [Natalizumab]

Formula M.Wt

Solubility Storage Store at 4°C, do not freeze

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

Background

Natalizumab is a recombinant, humanized monoclonal antibody, binds to $\alpha 4\beta 1$ -integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses[1].

Natalizumab, a recombinant, humanized antibody, binds to $\alpha 4\beta 1$ -integrin and blocks its interaction with VCAM-1. As a result, leukocyte migration into brain tissue is inhibited, reducing inflammation and preventing the formation of lesions. Natalizumab may also inhibit ongoing central nervous system (CNS) inflammation, mediated by leukocytes already present in the CNS, by interrupting the interactions between $\alpha 4$ -integrin-expressing leukocytes and extracellular matrix proteins such as fibronectin and osteopontin[1].

Natalizumab binds rapidly and with high affinity to $\alpha 4$ -integrin. Maximal binding ($\geq 80\%$ saturation), measured in vitro on isolated lymphocyte membranes, occurred 24 hours

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

after intravenous (IV) doses of natalizumab 1 mg/kg to 6 mg/kg[1].

[1]. Hutchinson M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007 Jun;3(2):259-68.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA